| |
|
 |
HOME | Business Introduction | Anti-cancerdrug |
|
|
| |
 |
| |
 |
|
| |
Our anti-cancer drug is a cell treatment drug that branches hematopoietis stem cells derived from mobilized peripheral blood to dendritic stem cells. Unlike existing anti-cancer drugs it hardly has any side effects or pain, and is nontoxic. We have domestic and foreign patents registered for the dendritic cell branching technology, and are in the process of clinical tests for renal cell carcinoma, breast cancer, ovarian cancer, prostate cancer and glioblastoma at Seoul Asan Hospital and other hospitals.
|
| |
|
 |
| |
 |
| |
Despite the rapid development of modern medicine and science, cancer, brain nervous system disorders and heart disorders are the 3 biggest causes of death, and the number of patients suffering from these diseases is increasing as society is aging. Surgery, radiation and chemical methods have rapidly developed even more in the past 30 years and many new drugs have developed too, yet the survival rate of cancer patients has not increased at all and a new treatment approach is desperately needed. Research on tumor immunity have shown that cancer is closely linked to the immunity system which is a natural protection mechanism, and so there is a high chance the most fundamental and safe way to treat this disease is to normalize the body's protective system. |
| |
|
| |
Directly using effective cells such as cytotoxic T cells and activating them is a method of immunity cell treatment being attempted, but more recently anti-cancer treatments using dendritic cells(DC) is being sought much more. It is now known that T cell knows that tumors are a foreign substance and reacts in a protective way to the antigen. It has been revealed that in order for the T cell to recognize the antigen and activate as an effector cell (cytotoxic T cell, helper/CD4+ T cell), an antigen presenting cell (APC) is necessary to introduce the antigen. A strong APC is needed to add to low antigenic, and present the surface antigen or signal down-regulating tumor to the immunization system. The dendritic cell was found by Steinman and Cohn in 1973 as a strong activator of the resting/naive T cell by a highly specialized APC. It is known that the reason why DC, known as "nature's adjuvant," can provoke strong immunity functions without adjuvant is because it manifests not only MHC class molecules (I/II) on the surface of cells as APC, but also co-stimulatory molecules (CD80, CD86) and adhesion molecules (e.g. ICAM-1). Study results on the formation of cytotoxic T lymphocyte/CTL due to DC and multiplication and activation of CD4+ helper T cell (Th1 type) are being published, and in vivo experiments are showing that DC injected into the body also stimulates formation of CTL. |
| |
|
| |
Therefore studies are showing that DC which plays a core role in controlling immunization of the body, 1) not only controls cell immunity related to cancer, 2) but controls immunity of allergic disorders such as asthma and rhinitis, and 3) self-immunity disorders such as diabetes, thyroiditis and arthritis, and 4) even interferes with the control of rejection reaction after liver, kidney or heart transplants. Based on the basic DC research results, securing technology that can cultivate DC appropriately for certain disorders would lead to a possibility of a safe and effective new treatment for terminal illnesses including cancer. |
| |
|
| |
FCB-Pharmicell has a DC producing technology patent that is largely differentiated from normal bone marrow DC cultivation technology in means of the kinds of cells, possibility of mass-production and cultivation place. The anti-cancer DC cultivation technology derived from CD34+ cell, which is patented, 1) is different from the existing method that starts from peripheral blood in that mass-production is possible due to the large number at hand, 2) and expressed CD8+lymphoid marker whilst secreting IFN-r, an anti-cancer effector molecule, and therefore gives hope of anti-cancer treatment through effective immunity cell control. 3) In addition the new cultivation method uses cytokine, for a more effective clinical approach. |
| |
|
| |
 |
| |
|
| |
Cancer is the number 1 cause of death amongst disorders, and as society grows older, the number of patients suffering from cancer will increase. Surgery, radiation and chemical methods have rapidly developed even more in the past 30 years and many new drugs have developed too, yet the survival rate of cancer patients has not increased at all and a new treatment approach is desperately needed. |
| |
|
| |
1) Tumor formation and immunity function
When normal cells turn into cancer cells, a substance that was no on the surface of the cell appears (tumor antigen), and when this substance is recognized it leads to
an antibody reaction and cell immunity reaction, and ultimately cancer cells are stopped from multiplying and are destroyed, to rid the body of cancer cells. However if immunity functions decrease or disappear for some reason the tumor cannot be stopped and it goes on to become clinical cancer. However, it has been revealed that anti-tumor immunity cell functions can revive through biological stimulation, showing us there is a chance of tumor immunity treatment. T cells and NK cells recognize and kill tumor cells as part of the normal immunity system of the body, and play an important part in activating immunity functions. It is important for the T cell to be aware of antigens in its activation process, and DC is the strongest antigen presenting cell known to be in the body. |
| |
|
| |
Actual cases of cancer patients showed that patients with more DC's had a higher survival rate, and low rate of cancer spreading in the body. Therefore DC is important in relation to anti-cancer. Most treatment attempts of cancer patents using DC used peptide and treated malignant melanoma, prostate cancer and malignant blood cancer patients, and 10 to 30 percent of the patients that did not have much reaction to existing treatments showed significant treatment effects. |
| |
|
| |
2) Advantages of immunity treatment as a new treatment method
Immunization theory and basic research results show that DC immunity treatment does not harm normal structures and has the theoretical advantage of only attacking cancer cells, and clinical results sow that there is hardly any body poisoning nor aftereffects. In addition, immunity treatment can be used widely, (1) not only for cancer relapse, but also for (2) remaining microscopic cancer after surgery, (3) prevention of cancer spreading to the body due to touching the tumor during surgery or movement of the cancer cells, (4) treatment of small cancer that moved in the beginning of treatment but was missed, (5) and as a vaccine to prevent cancer relapse. |
| |
|
| |
 |
| |
Lymphopoiesis dendritic cell's secretion of interferon-gamma ELISA (A) and ELISPOT (B) results |
| |
|
| |
 |
| |
MRI picture of a malignant nerve gliocytoma patient reacting from dendritic cell from hematopoiesis stem cell treatment
|
| |
|
| |
 |
| |
|
| |
 |
| |
|
| |
Our company holds domestic and international patents in the manufacturing technology of dendriform cell, an immunocyte and is currently undergoing investigator's trial utilizing the said technology in several institutes including the Seoul Asan Medical Center. Unlike the existing carcinostatic therapeutics, dendriform cell therapeutics is innoxious, causing little or no side effects and pain. However, in order to receive approval as a new carcinostatic drug, additional documents proving the validity and safety must be submitted. Pharmicell takes one step at a time to thoroughly overcome the preliminary stage to reach commercialization. |
| |
|
| |
 |
| |
*Brand number 40-0726300 Cancer therapeutics brand name |
|
 |
| |
| |
| |
|
|
